Turkey Aims To Bargain With Drug Firms To Ease Costs And Shortages
This article was originally published in PharmAsia News
Executive Summary
Turkey’s latest plan to ease shortages of mainly imported drugs for oncology and other chronic diseases while keeping a lid on reimbursement costs is to strike bargains with individual firms. But industry analysts are skeptical that systemic problems linked to exchange rate terms and growing demand will be solved by a new draft regulation allowing the Social Security Institution of Turkey, or SGK, to reach such deals.